Wugen

Focus: Wugen is a St. Louis-based biotechnology company specializing in off-the-shelf cell therapies for cancer, focusing on NK cell and CAR-T approaches in oncology.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Wugen

AI assessmentNot Hiring

No open roles listed right now. Follow Wugen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Genetic: WU-CART-007

T-cell Acute Lymphoblastic Leukemia

N/A

Clinical Trials (1)

NCT05509855A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

N/A

Help build intelligence for Wugen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage cell therapy innovator with diversified pipeline across NK cells and CAR-T modalities targeting high-unmet-need hematologic and solid tumors
Lean team environment (2 active roles) offers hands-on exposure to multiple programs from Phase 1 through Phase 2 development
Located in St. Louis with active hiring in critical CMC and Clinical functions, suggesting expansion phase

Watch Out For

Pre-revenue biotech with no disclosed funding or financial data creates uncertainty around cash runway and long-term viability
Minimal public presence (0 publications) and very early pipeline (no Phase 3 programs, no near-term FDA catalysts) means 5+ year horizon to value realization

Generated by Claude from Wugen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

WU-CART-007

T-Cell Non-Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT05377827Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Phase 1

WU-NK-101 - Dose Escalation

Colorectal Cancer Metastatic

Phase 1

Clinical Trials (1)

NCT05674526A Phase 1b Study of WU-NK-101 in Combination With Cetuximab

Phase 1

WU-CART-007

T-cell Acute Lymphoblastic Leukemia

Phase 1

Clinical Trials (1)

NCT04984356A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Phase 1

WU-NK-101

Acute Myeloid Leukemia

Phase 1

Clinical Trials (1)

NCT05470140A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase 1

CIML NK Cell Infusion

Acute Myeloid Leukemia

Phase 1/2

Clinical Trials (1)

NCT03068819Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Phase 1/2

Cytokine-induced memory-like NK cells

Relapsed Acute Myeloid Leukemia

Phase 2

Clinical Trials (1)

NCT04893915Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

Phase 2

WU-CART-007

T-cell Acute Lymphoblastic Leukemia

Phase 2

Clinical Trials (1)

NCT06514794A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline